SCHEMBL2645103

SCHEMBL2645103

Oc1ccc(-c2ccccn2)nc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.61
LMNA P02545 3/20 0.61
P4HTM Q9NXG6 3/20 0.61
CCR1 P32246 3/20 0.61
CCR5 P51681 3/20 0.61
CCR8 P51685 3/20 0.61
CYP1A2 P05177 1/20 0.61
POLB P06746 1/20 0.61
METAP1 P53582 1/20 0.61
BLM P54132 1/20 0.61
HIF1A Q16665 1/20 0.61
DOHH Q9BU89 1/20 0.61
TP53 P04637 3/20 0.58
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
ALOX15 P16050 2/20 0.58
HTT P42858 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
L3MBTL1 Q9Y468 2/20 0.58
ALDH1A1 P00352 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30516908 1.00 KDM4E (0.61) KDM4ELMNAP4HTMCCR1CCR5
SCHEMBL29705476 1.00 KDM4E (0.61) KDM4ELMNAP4HTMCCR1CCR5
SCHEMBL1070654 0.83 CCR1 (0.46) KDM4ELMNAP4HTMCCR1CCR5
SCHEMBL30958843 0.83 CCR1 (0.46) KDM4ELMNAP4HTMCCR1CCR5
SCHEMBL24302699 0.80 ALDH1A1 (0.52) KDM4ELMNAP4HTMCCR1CCR5
Dipyridyl SCHEMBL27648895 0.79 KDM4E (0.70) KDM4ELMNAP4HTMCCR1CCR5
Dipyridyl SCHEMBL28330098 0.79 KDM4E (0.70) KDM4ELMNAP4HTMCCR1CCR5
SCHEMBL163378 0.79 KDM4E (0.78) KDM4ELMNAP4HTMCCR1CCR5
Dipyridyl SCHEMBL27651116 0.78 KDM4E (0.88) KDM4ELMNAP4HTMCCR1CCR5
Dipyridyl SCHEMBL29907716 0.78 KDM4E (1.00) KDM4ELMNAP4HTMCCR1CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116536719-A Identification code for lead frame and silver plating process thereof 安徽立德半导体材料有限公司 2023-08-04 CN claimed
CN-116536719-A Identification code for lead frame and silver plating process thereof 安徽立德半导体材料有限公司 2023-08-04 CN disclosed
US-11377436-B2 EAAT2 enhancing molecules THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2022-07-05 US disclosed
US-20210163440-A1 EAAT2 ENHANCING MOLECULES BRIGHAM & WOMENS HOSPITAL INC (US) 2021-06-03 US disclosed
US-10203333-B2 Electronically neutral metal complexes as biological labels RUBIPY SCIENTIFIC, INC. (CA) 2019-02-12 US disclosed
WO-2019014460-A1 EAAT2 ENHANCING MOLECULES THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2019-01-17 WO disclosed
US-20160146826-A1 Electronically Neutral Metal Complexes As Biological Labels HUNAN SANSURE ACCUCISE BIOTECHNOLOGY CO., LTD. (CN) 2016-05-26 US disclosed
US-20160146826-A1 Electronically Neutral Metal Complexes As Biological Labels HUNAN SANSURE ACCUCISE BIOTECHNOLOGY CO., LTD. (CN) 2016-05-26 US disclosed
WO-2014203067-A1 ELECTRONICALLY NEUTRAL METAL COMPLEXES AS BIOLOGICAL LABELS RUBIPY SCIENTIFIC, INC. (CA) 2014-12-24 WO disclosed
EP-1702919-B1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE MSD KK (JP) 2012-05-30 EP disclosed
US-7728025-B2 2-heteroaryl-substituted benzimidazole derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-06-01 US disclosed
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative MSD K.K. (JP) 2008-03-20 US disclosed
EP-1824839-A2 SUBSTITUTED BIARYL ANALOGUES NEUROGEN CORPORATION (US) 2007-08-29 EP disclosed
EP-1702919-A1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-09-20 EP disclosed
WO-2006071538-A2 SUBSTITUTED BIARYL ANALOGUES NEUROGEN CORPORATION (US) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210163440-A1 EAAT2 ENHANCING MOLECULES SLC1A2, SLC1A1, SLC1A3 KDM4E 3651/4885LMNA 4504/4885P4HTM 1491/4885
US-10203333-B2 Electronically neutral metal complexes as biological labels MB, MCU, LETM1 KDM4E 2185/4885LMNA 532/4885P4HTM 2681/4885
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative GCK, GCKR, HK1 KDM4E 2940/4885LMNA 3434/4885P4HTM 4396/4885
US-11377436-B2 EAAT2 enhancing molecules SLC1A2, SLC1A1, SLC1A3 KDM4E 3651/4885LMNA 4504/4885P4HTM 1491/4885
US-20160146826-A1 Electronically Neutral Metal Complexes As Biological Labels MB, MCU, LETM1 KDM4E 2185/4885LMNA 532/4885P4HTM 2681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.